245 results about "Viral load" patented technology

Porcine circovirus-2 (PCV-2) is a recently identified agent wherein the potential spectrum of PCV-2-associated disease has been expanded by evidence of vertical and sexual transmission and associated reproductive failure in swine populations. PCV-2 was isolated from a litter of aborted piglets from a farm experiencing late term abortions and stillbirths. Severe, diffuse myocarditis was present in one piglet associated with extensive immunohistochemical staining for PCV-2 antigen. Variable amounts of PCV-2 antigen were also present in liver, lung and kidney of multiple fetuses. Inoculation of female pigs with a composition including an immunogen from PCV-2 or an epitope of interest from such an immunogen or with a vector expressing such an immunogen or epitope of interest prior to breeding, such as within the first five weeks of life, or prior to the perinatal period, or repeatedly over a lifetime, or during pregnancy, such as between the 6th and 8th and/or the 10th and 13th weeks of gestation, can prevent myocarditis, abortion and intrauterine infection associated with porcine circovirus-2. In addition, innoculation of male and/or female pigs with the aforementioned compositions can be carried out to prevent transmission of PCV-2 from male to female (or vice versa) during mating. Thus, the invention involves methods and compositions for preventing myocarditis, abortion and intrauterine infection associated with porcine circovirus-2.

The present invention provides a composition comprising HMB and at least one amino acid. The present invention also provides a method for the treatment of disease-associated wasting of an animal, a method for decreasing the serum-level of triglycerides of an animal, a method for decreasing the serum viral load of an animal, and a method for redistributing fat in an animal having a visceral region and a subcutaneous region. All methods comprise administering to the animal a composition comprising HMB and at least one amino acid.

The invention is based on the discovery that certain membranes, which include side chains or molecular “brushes” having, for example, tertiary amino functional groups, can be used as highly effective filters to capture viruses/virus particles from liquids without removal of proteins. New methods based on this discovery include removing viruses from liquids such as blood or plasma, removing viruses from pharmaceuticals, concentrating and/or purifying viruses, e.g., for use in gene therapy, and producing recombinant viruses in new bioreactors. The invention also includes new methods of therapy or adjunct therapy for viral infections, in which a patient's blood or plasma is filtered through the membranes to remove viruses to reduce the viral load. The invention also includes new bioreactors and viral filters containing the membranes.

The invention provides a SARS-CoV-2 vaccine using human type-5 replication-defective adenovirus as a vector. The vaccine uses E1 and E3 to be combined with replication-defective human type-5 adenovirus as the vector and HEK293 cells integrating adenovirus E1 gene as a packaging cell line, and a protective antigen gene carried is the 2019 SARS-CoV-2 S protein gene (Ad5-nCoV) which is subjected to optimization design. After the S protein gene is optimized, the expression level in transfected cells is increased significantly. The vaccine has good immunogenicity in mouse and guinea pig models, andcan induce a body to produce a strong cellular and humoral immune response in a short time. Studies on the protective effect of hACE2 transgenic mice show that after 14 days of single immunization ofAd5-nCoV, the viral load in lung tissue can be significantly reduced, and it is indicated that the vaccine has a good immunoprotective effect on the 2019 SARS-CoV-2. In addition, the vaccine is quick, simple and convenient to prepare, and can be mass-produced in a short period of time to respond to sudden outbreaks.

The present disclosure encompasses compositions comprising a surfactant, and an acid such as, but not limited to, levulinic acid, that together have a synergistic effect in reducing the viability of a virus population compared to the efficacy of the individual compounds. This synergy allows the formulation of compositions where the active agents (including an acid and a surfactant) are present at concentrations effective to inactivate viruses on surfaces, including human skin. The viricidal compositions disclosed herein are efficacious without damaging the surface to which they may be applied, or even altering the organoleptic properties of a treated food substance. The viricidal compositions and wipes containing such compositions are suitable for sanitizing any surface suspected of having a viral load thereon, or where it is desirable to ensure that a viral load is as low as possible.

Methods for treating Hepatitis infections are provided. In one embodiment, an initial dosage of interferon is administered to a patient, and interferon serum levels and viral load data is collected over time. This data can be used to determine patient-specific pharmacokinetic and pharmacodynamic parameters and then construct patient-specific interferon delivery profiles. Patient-specific delivery profiles can then be used to design patient-specific therapeutic regimens.

This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5⁺CD4⁺ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4⁺ cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5⁺CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

The present invention pertains to a composition comprising Ibogaine, an indole alkaloid, its active salts and its principal metabolite noribogaine, a demethylated form of ibogaine, for the treatment of hepatitis C and hepatitis C related complications, administered in single or multiple dose regimens effective to reduce somatic complaints, liver enzyme values and viral load caused by chronic hepatitis C in patients, and methods of using the same.

The present invention relates to novel benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of benzimidazole compounds as inhibitors of membrane fusion associated events, such as viral transmission. In another embodiment, the invention encompasses processes for making benzimidazole compounds, methods of using the benzimidazole compounds and compositions comprising the benzimidazole compounds. Finally, the invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compounds of the invention.

The present invention provides a device, system, and methods of use comprising an absorbent hydrophobic polyolefin matrix, and methods of use thereof, for storage, preserving, and recovering liquid suspension of biological specimens containing analytes of interest in a dry state. The dried biological specimens containing analytes of interest absorbed on the polyolefin matrix are reconstituted such as with molecular-grade water and released by compressing the polyolefin matrix. The reconstituted biological analytes are qualified for subsequent analysis, such as for qualitative and quantitative analysis of viral nucleic acids, such a viral load testing, genotyping, and sequencing. Also provided are kits with instructions, and methods of use thereof, for storage, preserving, and recovering biological specimens containing analytes of interest using the compression device of the invention.

A nanoplasmonic platform can be used for the detection and quantification of multiple HIV subtypes in whole blood with localized surface plasmon resonance. Among other things, this nanoplasmonic platform provides a viable way to detection and quantification of viral load at a point of care with significantly less cost, time, and laboratory resources than existing methods of detection. Although an example of HIV detection in whole blood is provided, the nanoplasmonic platform is adaptable to detect other pathogens and infectious agents or macromolecules.

The invention discloses a nucleic acid detection kit for human papilloma virus, a use method and an application thereof. The kit includes a nucleic acid amplification reagent comprising a primer pair and a probe corresponding to the primer pair. The use method of the kit includes the following steps: 1) extracting nucleic acids from a sample; 2) preparing the reagent; 3) performing PCR amplification; and 4) performing fluorescent detection to a PCR amplification reaction product at 65-72 DEG C, and determining infection type of the HPV according to the changes on the Ct value of a target amplification curve and the Ct value of an internal standard amplification curve. The kit can be used for detecting low-risk and high-risk human papilloma virus and for typing the human papilloma virus. The kit can be used for calculating relative viral load of the HPV, can avoid pollution, can increase treatment throughput of samples, and can avoid missing detection.

Methods and compositions for treatment of human immunodeficiency virus (HIV) infections have been developed which dampen immune activation with a bias more on the CD4 T cells relative to the CD8 T cell response, inhibit HIV replication, reactivate latent HIV, and inhibit infection of cells by HIV. Pushing latent HIV into active infections with hindrance of cell infection by the reactivated HIV can substantially reduce the number of cells infected with HIV and the viral load of HIV, which is not achieved using just the combination of ART and compounds which activate latent HIV. The methods involve administering to an HIV-infected subject three or more compounds which collectively dampen immune activation with a bias more on the CD4 T cells relative to the CD8 T cell response, inhibit HIV replication, reactivate latent HIV, and inhibiting infection of CD4 T cells by HIV.

The invention discloses a digital PCR-based novel coronavirus nucleic acid quantitative detection kit and an application. The reaction total system of the digital PCR-based novel coronavirus nucleic acid quantitative detection kit has 20 ul, comprising 10ul of 2x One-Step RT-ddPCR Supermix, 0.8ul of 25mM manganese acetate solution, 5ul of to-be-detected sample RNA, 1ul of ORFlab gene primer probeworking solution, 1ul of N gene primer probe working solution, 1ul of RPP30 gene primer probe working solution and 1.2ul of Nuclease-Free Water, wherein 5ul of negative control RNA extraction solutionand 5ul of positive control RNA extraction solution are adopted to replace the to-be-detected sample RNA in a negative control reaction system and a positive control reaction system respectively. Based on the innovative RNA one-step reverse transcription microdroplet type digital PCR technology, nucleic acid absolute quantification is carried out specific to highly conservative ORFlab gene and Ngene in the novel coronavirus (2019-nCoV) genome, so that the detection accuracy is improved, and the kit can be used for clinical assisted diagnosis and viral load analysis of novel coronavirus (2019-nCoV) infection, and has a wide clinical application value.

First generation adenoviral vectors and-recombinant adenovirus-based HIV vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof are described. The adenovirus vaccines, when directly introduced into living vertebrate tissue, express the relevant proteins, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, HIV-1 Pol, HIV-1 Nef, and derivatives thereof. The adenoviral vaccines of the present invention, alone or in combination, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

The invention provides a novel viral vaccine for treating a non-small cell lung cancer and a preparation method thereof. The preparation method of the viral vaccine comprises the first step of constructing a carrier of an MVA virus and the second step of obtaining specificity presenting MAGE-3 antigen DC cells. According to the viral vaccine prepared through the method, the biological stability is high, adverse effects on human bodies are not produced, and pathogenic dangers do not exist; a virus antibody can obtain a large number of viral particles with high purity easily; MAGE-A3 expressed by the viral vaccine has better immunogenicity, more epitopes are achieved, and drug resistance is not prone to being caused; the viral load needed in inoculation of the viral vaccine is smaller than other viruses.

The invention belongs to the field of microbial molecular detection, and particularly relates to a kit for flavivirus quick typing and virus load detection. The kit for flavivirus quick typing and virus load detection comprises specific primers and probes for flaviviruses, including specific primers and a probe for dengue virus, specific primers and a probe for Zika virus, specific primers and a probe for yellow fever virus, and specific primers and a probe for Chikungunya virus. The kit for flavivirus quick typing and virus load detection has the advantages of high detection speed and accurate detection and quantification results, can simultaneously detect 3 different flavivirus pathogens and 1 togavirus pathogen capable of causing similar clinical symptoms at one time, can detect and diagnose flavivirus-pathogen-infected suspicious cases in time, and enhances the detection accuracy of flavivirus pathogen infection.

The present invention provides a human immunodeficiency virus type 1 one-step fluorescence quantitative RT-PCR detection kit, which comprises a RT-PCR reaction solution, a RT-PCR enzyme mixture, a primer probe, a negative control, a strong positive control, a weak positive control, and calibration substances No.1-5. According to the present invention, a one-step fluorescence quantitative reaction can be directly performed on the extracted HIV-1RNA, the virus loading of the HIV-1RNA in a sample can be detected, the reference gene is adopted as the internal control, and the UNG enzyme is adopted to prevent pollution; and the kit has characteristics of simple one-step amplification method, short procedure, easy operation, pollution prevention, strong detection result specificity, high sensitivity, clear result and high result reliability, and can be used for detection of the virus loading of the human immunodeficiency virus type 1 (HIV-1) RNA in blood serum.

This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log₁₀ to 2.5 log₁₀ at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log₁₀ at about nine days following administration of the CCR5 receptor antagonist.